These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 15921532)

  • 1. APOBEC3G & HTLV-1: inhibition without deamination.
    Strebel K
    Retrovirology; 2005 May; 2():37. PubMed ID: 15921532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC3G targets human T-cell leukemia virus type 1.
    Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
    Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
    Holmes RK; Koning FA; Bishop KN; Malim MH
    J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary function of the two catalytic domains of APOBEC3G.
    Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
    Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent advances in the study of mechanism of APOBEC3G against virus].
    Zhu YP; Jiang JD; Peng ZG
    Yao Xue Xue Bao; 2014 Jan; 49(1):30-6. PubMed ID: 24783502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
    Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
    J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.
    Suspène R; Sommer P; Henry M; Ferris S; Guétard D; Pochet S; Chester A; Navaratnam N; Wain-Hobson S; Vartanian JP
    Nucleic Acids Res; 2004; 32(8):2421-9. PubMed ID: 15121899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons.
    Jost S; Turelli P; Mangeat B; Protzer U; Trono D
    J Virol; 2007 Oct; 81(19):10588-96. PubMed ID: 17652382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.
    Nguyen DH; Gummuluru S; Hu J
    J Virol; 2007 May; 81(9):4465-72. PubMed ID: 17314171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.
    Kremer M; Schnierle BS
    Curr HIV Res; 2005 Oct; 3(4):339-44. PubMed ID: 16250885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    Bishop KN; Holmes RK; Malim MH
    J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
    Goncalves J; Santa-Marta M
    Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
    Franca R; Spadari S; Maga G
    Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
    Santa-Marta M; Aires da Silva F; Fonseca AM; Rato S; Goncalves J
    Mol Immunol; 2007 Jan; 44(4):583-90. PubMed ID: 16580072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
    Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.
    Derse D; Hill SA; Princler G; Lloyd P; Heidecker G
    Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2915-20. PubMed ID: 17299050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Marin M; Rose KM; Kozak SL; Kabat D
    Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.